NEW YORK (GenomeWeb News) – Gentel Biosciences today said that it hasacquired the SilverQuant trademark from Eppendorf, which it will apply to its protein array technology platform.
Madison, Wis.-based Gentel said the acquisition of the trademark complements its other initiatives to grow its market position as a provider of multiplexed proteomic tools.
In 2008, Gentel had acquired from Eppendorf the rights to array-basedchromogenic detection technology that uses gold particle-enhanced silver crystal deposition for detection and quantification of arrays. Today, it said that the SilverQuant technology works with the Gentel Proteomics Multi-System, which integrates chromogenic scanning and analysis of arrays at a price comparable to a benchtop ELISA system.
"The SilverQuant name accurately describes our unique chromogenic detection technology as well as its application to protein quantitation," Gentel VP of Commercial Development Dan Clutter said in astatement. "Further, SilverQuant is a strong trademark that adds a valuable intangible asset to the company given its worldwide registration and existing prestige in the life sciences."
Financial terms of the trademark acquisition were not disclosed.
